Roswell Park Hires Chief Pharmacy Officer

Dr. Lijian Cai to examine pharmaceutical trends, operations as he oversees program at cancer center Dr. Cai brings knowledge of medication safety, pharmaceutical training Oversees operations on main campus, and outpatient pharmacy, hospital-based satellite locations Advocate of pharmaceutical industry transparency in wake of recent drug shortages BUFFALO,

Read more

How Stress Weakens Immunity Against Cancer

Roswell Park Team Helps Explain How Chronic Stress Weakens Immunity Against Cancer Researchers identify new mechanism associated with aggressive growth in cancer tumors Team found chronic stress can increase MSDC cells, leading to tumor growth One of the first studies to explain the impacts of stress on

Read more

Clinical Trials and Childhood Hodgkin Lymphoma

Access to Clinical Trials May Drive Differences in Outcome Among Childhood Hodgkin Lymphoma Patients COG study looks to explain lower survival rate for nonwhite children and adolescents with disease Study is latest to report lower survival for blacks, Hispanics with the disease Multicenter team set out to

Read more

Clinical Trial for Brain Cancer Glioblastoma Immunotherapy SurVaxM

Roswell Park Spinoff Company Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM MimiVax LLC and Roswell Park to launch large clinical trial at centers in U.S. & abroad following major licensing deal MimiVax LLC secures $10 million upfront in licensing deal Large phase II studies expected

Read more

How Baby Aspirin Helps in the Fight Against Cancer

What if a drug that sits in nearly everyone’s medicine cabinet could help extend the lives of some cancer patients? In companion presentations at the American Society for Therapeutic Radiation Oncology (ASTRO) Annual Meeting in Chicago, doctors from Roswell Park Comprehensive Cancer Center report new evidence that

Read more

Reduced Therapy for Children with Neuroblastoma

Algorithm Reduces Need for Therapy in Children With Intermediate-Risk Neuroblastoma COG study shows treatment can be reduced without compromising outcomes – shows therapy can be reduced in some neuroblastoma patients Algorithm based on tumor biology, anticipated response to treatment for patients with localized tumors, 3-year overall survival

Read more